Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.43 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.43 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.43 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.43 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.43 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.43 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736362 | 0.88 | TAAR1 (0.81) | TAAR1SMN1; SMN2LMNATSHRHIF1A | |
| SCHEMBL1736364 | 0.88 | TAAR1 (0.81) | TAAR1SMN1; SMN2LMNATSHRHIF1A | |
| SCHEMBL1736065 | 0.79 | TAAR1 (0.67) | TAAR1SMN1; SMN2LMNATSHRHIF1A | |
| SCHEMBL1736064 | 0.79 | TAAR1 (0.67) | TAAR1SMN1; SMN2LMNATSHRHIF1A | |
| Hydrochloric Acid SCHEMBL4739119 | 0.70 | GRIN2B (0.53) | TAAR1SMN1; SMN2HIF1A | |
| SCHEMBL1737052 | 0.70 | GRIN1 (0.62) | TAAR1SMN1; SMN2LMNAHIF1AADRA2A | |
| SCHEMBL558594 | 0.66 | NOS1 (0.37) | — | |
| Hydrochloric Acid SCHEMBL19520756 | 0.64 | GRIN2D (0.55) | TAAR1SMN1; SMN2HIF1AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27636313 | 0.64 | GRIN2B (0.55) | TAAR1HIF1ASLC22A2SLC22A1ADRA2A | |
| Hydrochloric Acid SCHEMBL28464112 | 0.64 | GRIN1 (0.50) | TAAR1HIF1AADRA2ACYP2D6ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4602054-A1 | FUSION PROTEINS COMPRISING A CELL SURFACE MARKER SPECIFIC VHH | Universitätsklinikum Hamburg-Eppendorf (DE) | 2025-08-20 | — | — | EP | claimed |
| WO-2024079132-A1 | FUSION PROTEINS COMPRISING A CELL SURFACE MARKER SPECIFIC VHH | Universitätsklinikum Hamburg-Eppendorf (DE) | 2024-04-18 | — | — | WO | claimed |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TALLAC THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260061086-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| US-12427210-B2 | Compounds comprising a fibroblast activation protein ligand and use thereof | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-30 | — | — | US | disclosed |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| EP-4602054-A1 | FUSION PROTEINS COMPRISING A CELL SURFACE MARKER SPECIFIC VHH | Universitätsklinikum Hamburg-Eppendorf (DE) | 2025-08-20 | — | — | EP | disclosed |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | Tallac Therapeutics, Inc. (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2025088080-A1 | SURFACE MARKER BINDING DOMAIN INSERT IN VP3 CAPSID PROTEIN OF AAV AND METHOD FOR PRODUCING RECOMBINANT AAV | Universitätsklinikum Hamburg-Eppendorf (DE) | 2025-05-01 | — | — | WO | disclosed |
| EP-3706141-B1 | RADIOISOTOPE PRODUCTION METHOD AND RADIOISOTOPE PRODUCTION DEVICE | NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECH (JP) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025061686-A1 | POLYNUCLEOTIDES AND USES IN THE TREATMENT OF PRADER-WILLI SYNDROME (PWS) AND /OR PRADER-WILLI LIKE SYNDROME | UNIVERSITÉ DE LORRAINE (FR) | 2025-03-27 | — | — | WO | disclosed |
| WO-2023021186-A1 | ANTIGEN-BINDING POLYPEPTIDES AGAINST CD73 | Universitätsklinikum Hamburg-Eppendorf (DE) | 2023-02-23 | — | — | WO | disclosed |
| EP-4137515-A1 | ANTIGEN-BINDING POLYPEPTIDES AGAINST CD73 | Universitätsklinikum Hamburg-Eppendorf (DE) | 2023-02-22 | — | — | EP | disclosed |
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-10-06 | — | — | US | disclosed |
| US-20220273831-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-09-01 | — | — | US | disclosed |
| CN-114721333-A | Automatic control system of rubber vehicle for pressing and releasing hydraulic arm of natural rubber production line | 海南大学 | 2022-07-08 | — | — | CN | disclosed |
| US-20220184238-A1 | Radiolabeled Compound Producing Method and Producing Apparatus, Radiolabeled Compound and Radioisotope Producing Apparatus | NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) | 2022-06-16 | — | — | US | disclosed |
| US-11276506-B2 | Producing method of radioisotope and radioisotope producing apparatus | National Institutes for Quantum Science and Technology (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| EP-3950062-A1 | RADIOLABELED COMPOUND PRODUCTION METHOD AND PRODUCTION DEVICE, RADIO-LABELED COMPOUND, AND RADIOISOTOPE PRODUCTION DEVICE | National Institutes For Quantum Science And Technology (JP) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | ADRA2A 4050/4885ADRA2B 4587/4885SLC6A2 4861/4885 |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | ADRA2A 1054/4885ADRA2B 1118/4885SLC6A2 4187/4885 |
| US-20260061086-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FAP, FIBP, FGF23 | ADRA2A 4295/4885ADRA2B 4463/4885SLC6A2 1640/4885 |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TYMP, DUT, PAICS | ADRA2A 3887/4885ADRA2B 4359/4885SLC6A2 2769/4885 |
| US-20220273831-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FGF2, FRS2 | ADRA2A 4562/4885ADRA2B 4491/4885SLC6A2 4777/4885 |
| US-12427210-B2 | Compounds comprising a fibroblast activation protein ligand and use thereof | FIBP, FGF2, FRS2 | ADRA2A 4562/4885ADRA2B 4491/4885SLC6A2 4777/4885 |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | ADRA2A 3887/4885ADRA2B 4359/4885SLC6A2 2769/4885 |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | UNG, DUT, TYMP | ADRA2A 3984/4885ADRA2B 3937/4885SLC6A2 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.